ASCO Care and Treatment Recommendations for Patients

January 13, 2020

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed evidence-based recommendations to improve the accuracy of testing for estrogen and progesterone receptors for breast cancer. This guide for patients is based on ASCO’s and CAP’s recommendations.

May 23, 2016

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) provides recommendations on the use of hormonal therapy for metastatic breast cancer. This guide for patients is based on the most recent recommendations.

July 20, 2015

To help doctors provide their patients with the highest quality care, the American Society of Clinical Oncology (ASCO) developed a new guideline on using biomarkers to guide the treatment of metastatic breast cancer. This guide for patients is based on ASCO’s most recent recommendations.

July 13, 2015

ASCO recently updated a clinical practice guideline about the use of white blood cell growth factors. This patient guide is based on ASCO's recommendations.

September 2, 2014

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) asks its medical experts to develop evidence-based recommendations about specific topics in cancer care. These recommendations are for the treatment of human epidermal receptor 2 (HER2)-negative breast cancer that has spread beyond the breast to areas either nearby the breast or to distant parts of the body. This guide for patients and caregivers is based on ASCO's recommendations.

November 12, 2013

To help doctors provide their patients with the highest-quality care, the American Society of Clinical Oncology (ASCO) issued an endorsement of a guideline recently developed by Cancer Care Ontario. This guideline recommends tests and testing schedules for the follow-up care of patients who have completed treatment for colorectal cancer.

April 2, 2012

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations on giving doses of chemotherapy that are based on a patient’s actual weight. This guide for patients is based on ASCO recommendations and is intended for people who are obese.

July 25, 2011

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations on the usefulness of laboratory tests (called assays) to find out if a cancer might be resistant or sensitive to a specific chemotherapy treatment before it is offered to a patient. In 2011, this guideline was reviewed due to new research; this research continued to support the 2004 recommendations. This guide for patients is based on ASCO’s most recent recommendations.

June 7, 2010

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) developed evidence-based recommendations about the use of epoetin (Epogen, Procrit) or darbepoetin (Aranesp) for chemotherapy-related anemia. In 2010, this guideline was updated to reflect results of recent clinical studies and a new analysis of combined data on the use of these drugs. It also summarizes the changes to the U.S. Food and Drug Administration's (FDA's) approved prescribing recommendations. This guide for patients is based on the most recent ASCO and ASH recommendations.

August 16, 2004

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations for adjuvant chemotherapy for stage II colon cancer. This guide for patients is based on ASCO’s recommendations.